Renal Outcomes After Simultaneous Liver‐Kidney Transplantation: Results from the US Multicenter Simultaneous Liver‐Kidney Transplantation Consortium
Pratima Sharma,Zhiyu Sui,Min Zhang,John C. Magee,Pranab Barman,Yuval Patel,Aaron Schluger,Kara Walter,Scott W. Biggins,Giuseppe Cullaro,Randi Wong,Jennifer C. Lai,Jennifer Jo,Jasmine Sinha,Lisa VanWagner,Elizabeth C. Verna
DOI: https://doi.org/10.1002/lt.26032
2021-04-21
Liver Transplantation
Abstract:SLKT is increasingly common in the United States (US). However, little is known about the renal‐related outcomes following SLKT, which will be essential to maximize the health of these allografts. We examined the factors impacting renal function following simultaneous liver‐kidney transplant (SLKT). MethodsThis is an observational multicenter cohort study from the US Multicenter SLKT consortium consisting of recipients of SLKT aged ≥18 years performed between 2/2002‐6/2017 at six large US centers in six different United Network for Organ Sharing regions(UNOS). The primary outcome was incident post‐SLKT stage4‐5 chronic kidney disease(CKD) defined as <30ml/min/1.73m2 or listing for kidney transplant. ResultsThe median age (N=570) was 58 years(interquartile‐range:51‐64), 37% were female, 76% were white, 33% had hepatitis C, 20% had nonalcoholic steatohepatitis (NASH), and 23% had alcohol‐associated liver disease; 68% developed ≥stage3 CKD at the end of follow up. The 1‐, 3‐ and 5‐ year incidence of post‐SLKT stage4‐5 CKD was 10%, 12%, and 16%. Pre‐SLKT diabetes (HR=1.45[1.00‐2.15]), NASH(HR=1.58[1.01‐2.45]), and delayed kidney graft function(HR=1.72[1.10‐2.71]) were the recipient factors independently associated with high risk, whereas use of tacrolimus (HR=0.44[0.22‐0.89]) reduced the risk. Females (β=‐6.22±2.16ml/min/1.73 m2; P=0.004), NASH (β=‐7.27±3.27ml/min/1.73 m2;p=0.027) and delayed kidney graft function (β=‐7.25± 2.26ml/min/1.73 m2;P=0.007) were independently associated with low eGFR at last follow‐up. ConclusionsStage4‐5 CKD is common after SLKT. There remains an unmet need for personalized renal protective strategies, specifically stratified by sex, diabetes, and liver disease, to preserve renal function among SLKT recipients.
gastroenterology & hepatology,surgery,transplantation